Trial Profile
A Phase I Open-Label Study In Healthy Volunteers To Compare The Plasma Pharmacokinetics of Polymorph Form XLI AG-013736 In The Fasted And Fed State.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Breast cancer; Colorectal cancer; Gastrointestinal cancer; Non-small cell lung cancer; Renal cancer; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 05 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2009 New trial record